Placeholder Banner

New PhRMA report: Nearly 800 Cancer Medicines in Development

October 7, 2014
A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that biopharma companies are currently developing nearly 800 new medicines and vaccines for cancer.

“In recent decades, we have seen great progress in developing effective cancer treatments that help extend lives, improve quality of life and increase productivity,” said PhRMA President and CEO John J. Castellani. “Continued research has expanded our knowledge of how cancer develops and how to target medicines for specific cancer types, which has resulted in more effective therapies for patients.”

Cancer is the second leading cause of death in the U.S., accounting for nearly one of every four deaths, according to the American Cancer Society. More than 1.6 million new cancer cases will be diagnosed in 2014 alone and nearly 600,000 Americans are projected to die from cancer this year.

According to the report, of the 771 medicines and vaccines either in clinical trials or awaiting review by the U.S. Food and Drug Administration, there are 98 for lung cancer, 87 for leukemia, 78 for lymphoma, 73 for breast cancer, 56 for skin cancer and 48 for ovarian cancer.

View the full report on Medicines in Development for Cancer.